MGC Pharmaceuticals Ltd's (ASX:MXC) (OTCMKTS:MGCLF) (FRA:MGC) Roby Zomer caught up with Proactive's Andrew Scott following completion of its 50-patient Phase II double-blind, placebo-controlled clinical trial for anti-inflammatory treatment, ArtemiC, on patients diagnosed with COVID-19. Final results are expected to be published next month.
viewMGC Pharmaceuticals Ltd
MGC Pharma 'confident' following completion of ArtemiC Phase II COVID-19 trial
Quick facts: MGC Pharmaceuticals Ltd
Price: 0.0215 AUD
ASX:MXC
Market: ASX
Market Cap: $35.55 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
MGC Pharmaceuticals leads the way in phytocannabinoid derived medicines
Most read
Mining
Copper demand is rising, while inventory and supply are falling, creating a...
6 days, 19 hours ago
Mining
Proactive to host Gold Webinar on Tuesday November 24 as strong market...
5 days, 23 hours ago
Health
MGC Pharmaceuticals acquires Australian telehealth platform Medicinal...
2 days, 23 hours ago
Mining
Musgrave Minerals turns up the heat at Cue Gold Project with new discovery...
3 days, 4 hours ago
